In 2018, Alnylam seems poised to deliver its first big breakthrough. John Maraganore, CEO, sat down with LSL Chief Editor, Rob Wright, to share his perspectives on Alnylam’s upcoming year — including the good, the bad, and everything in-between.
Readers provide feedback and suggestions around how the biopharmaceutical industry could help the homeless during the annual J.P. Morgan Healthcare Conference in San Francisco.
The Conference Forum’s 2018 R&D Leadership Summit employs the Chatham House Rule, which limits what information can be revealed from the event's proceedings. As one of the only members of the media in the room, Chief Editor Rob Wright shares what he can from this year's event, which had the theme “Growth: Where Will It Come From?”
Clay Siegall, Ph.D., president, CEO, and chairman of Seattle Genetics, gives an exclusive interview about his company’s potential blockbuster, how they got to this point, and what’s next.
Print is not dead. In fact, Chief Editor Rob Wright believes we are on the verge of print’s resurgence, perhaps something similar to what’s being witnessed in the music industry with vinyl.
Rob Wright interviews Kate Merton, head of Johnson & Johnson Innovation’s newly created JLABS in New York City.
Rob Wright interviews Jeremy Levin, chairman and CEO of Ovid Therapeutics, about the BIO opioid crisis working group he is chairing.
Rob Wright video interviews Michael Margolis, R.Ph, head of life sciences and co-head of healthcare investment banking at Oppenheimer & Co. Inc. during the 2018 BIO CEO & Investor Conference in New York.
Rob Wright video interviews CytoSorbents’ CEO, Dr. Philip Chan, about CytoSorb, the company’s lead product described as a “Brita filter for your blood,” during the 2018 BIO CEO & Investor Conference in New York.